Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm-Reference-Cited by-同舟云学术

Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm

Published:2013-04-05 Issue:5 Volume:161 Page:667-676
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Barrio Santiago¹,Gallardo Miguel,Arenas Alicia¹,Ayala Rosa¹,Rapado Inmaculada¹,Rueda Daniel¹,Jimenez Ana¹,Albizua Enriqueta,Burgaleta Carmen²,Gilsanz Florinda¹,Martinez-Lopez Joaquin¹

Affiliation:

1. Haematology Service; Hospital Universitario 12 de Octubre; Madrid; Spain

2. Hospital Principe de Asturias; Alcala de Henares; Madrid; Spain

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12308/fullpdf

Reference36 articles.

1. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia;Albizua;Annals of Hematology,2011

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

3. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer;Byers;Clinical Cancer Research,2009

4. Developmental changes in the expression of transcription factors GATA-1, -2 and -3 during the onset of human medullary haematopoiesis;Dame;British Journal of Haematology,2002

5. FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis;Desterke;Cancer Research,2011

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands;Journal of Medicinal Chemistry;2022-06-02

2. Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma;Cancers;2022-02-20

3. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy;Leukemia;2021-09-03

4. Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma;PLOS ONE;2021-03-11

5. Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms;Cancers;2020-09-11